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Abstract: Cisatracurium besylate is an ideal non-depolarizing muscle relaxant which is widely used
in clinical application. However, some studies have suggested that cisatracurium besylate can affect
cell proliferation. Moreover, its specific mechanism of action remains unclear. Here, we found
that the number of GFP-LC3 (green fluoresent protein-light chain 3) positive autophagosomes
and the rate of mitochondria fracture both increased significantly in drug-treated GFP-LC3 and
MitoDsRed stable HeLa cells. Moreover, cisatracurium promoted the co-localization of LC3 and
mitochondria and induced formation of autolysosomes. Levels of mitochondrial proteins decreased,
which were reversed by the lysosome inhibitor Bafinomycin A1. Similar results with evidence of
dose-dependent effects were found in both HeLa and Human Umbilical Vein Endothelial Cells
(HUVECs). Cisatracurium lowered HUVEC viability to 0.16 (OD490) at 100 µM and to 0.05 (OD490)
after 48 h in vitro; it increased the cell death rate to 56% at 100 µM and to 60% after 24 h in a
concentration- and time-dependent manner (p < 0.01). Cell proliferation decreased significantly by
four fold in Atg5 WT (wildtype) MEF (mouse embryonic fibroblast) (p < 0.01) but was unaffected in
Atg5 KO (Knockout) MEF, even upon treatment with a high dose of cisatracurium. Cisatracurium
induced significant increase in cell death of wild-type MEFs even in the presence of the apoptosis
inhibitor zVAD. Thus, we conclude that activation of both the autophagic cell death and cell apoptosis
pathways contributes to cisatracurium-mediated cell injury.
Keywords: cisatracurium; autophagosome; apoptosis; mitochondria
1. Introduction
Cisatracurium besylate has some advantages such as strong and fast efficacy, quick recovery
without accumulation, good controllability and independence from liver and kidney [1,2]. Hence, it is
an ideal non-depolarizing muscle relaxant [3,4]. Although cisatracurium besylate has some clinical
advantages compared to other muscle relaxants, whether this drug has other side effects needs further
investigation [5,6]. In 2001, it was reported that cisatracurium besylate could affect proliferation of cells
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in vitro [7]. Another study found that the effect of cisatracurium besylate on cell proliferation could be
attributed to apoptosis caused by over-accumulated peroxides [8]. In the present study, we sought
to investigate whether long-term use of different doses of cisatracurium besylate will trigger cellular
injury and what is the mechanism of action of this drug.
During the early phase of formation of autophagosome (preautophagosome), the Atg12–Atg5-Atg16L
complex promotes the expansion of autophagic vacuole from a small vesicle to a semi-circular
structure. The direction of membrane extension depends on the position of the Atg5 complex,
i.e., the membrane stretches towards the Atg5 complex [9,10]. When the autophagic vacuole with
double-membrane structure develops a closed ring shape, the Atg5 complex detaches from the bilayer
membrane, leaving behind the membrane-bound light chain 3II (LC3II) in the autophagic vacuole [11].
The combination of Atg5 complex and autophagic vacuole membrane can also promote the transfer
and aggregation of microtubule-associated protein 1 light chain 3 (LC3) in autophagic vacuoles [9,10].
Autophagosomes can then fuse with lysosome membranes to form autolysosomes for subsequent
degradation of their contents [12,13].
Apoptosis, which is also called Type I programmed cell death (PCD), is characterized
morphologically by cell nuclear shrinkage and fragmentation, apoptotic body formation, chromosomal
DNA fragmentation, membranolysis and transfer of phosphatidylserine from the cell inner membrane
to the outer membrane [14–16]. Recent studies have found that besides apoptosis, PCD also includes
autophagic cell death (Type II programmed cell death) [17–20]. It is thought that moderate- to low-level
autophagy plays a protective role, but when autophagy occurs at a high level, it causes autophagic
cell death [21–24]. By focusing on the relationship between cisatracurium besylate and autophagic
cell death, the present study aimed to explore possible mechanisms behind the inhibitory effect of
cisatracurium besylate on proliferation of cultured cells in vitro.
2. Results
2.1. Cisatracurium Besylate Promotes Mitochondrial Breakage, Mitochondrial Protein Degradation and
Colocalization of Mitochondria and Autophagosomes
Selection of cisatracurium besylate concentration was done based on previous studies [2,7,8]. LC3,
a protein found on the membrane of autophagosomes, was labeled to track autophagosomes. LC3-I is
diffusely distributed in the cytoplasm while LC3-II accumulates on autophagosomes membranes [25].
Upon autophagy induction, cells accumulate large number of autophagosomes. The degree of
autophagy can be inferred based on the number of green fluorescent puncta in cell lines stably
transfected with GFP-LC3 [26–28]. In this study, HeLa cells stably transfected with GFP-LC3
(marks autophagosome-like structures) and MitoDsred (marks mitochondria) were treated with
different levels of cisatracurium besylate. Then, LC3 green fluorescent puncta in each cell were
counted. Three independent countings were carried out, with at least 100 randomly selected cells
used for each counting. With increase in drug concentration, the number of LC3-positive autophagic
structures increased in a concentration-dependent manner. Mitochondrial morphology was found
to be altered starting at a concentration of 5 µM (Figure 1A). Mitochondria were broken and formed
aggregates, and the severity of this phenotype increased with increasing drug concentration. Moreover,
colocalization between mitochondria and GFP-LC3 indicated that mitochondrial autophagy was
enhanced by the drug. At 100 µM, cell morphology changed from spindle to circular, and mitochondria
became more fragmented and aggregated around the nucleus, indicating the occurrence of excessive
mitochondrial autophagy (Figure 1A).
Longitudinal observation indicated that cisatracurium besylate could induce mitochondrial
autophagy. In addition, autophagosome number and mitochondrial morphology were also found to
change over time. HeLa cells stably transfected with GFP-LC3 and MitoDsred were treated with 5 µM
cisatracurium besylate at 0, 6, 12, and 24 h. After immobilization and mounting, cells were observed
under LCSM and the number of LC3 puncta in each cell was counted. Three independent counts
were done, with at least 100 cells randomly selected in each count. As treatment time increased, LC3
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aggregates also increased, showing time-dependent (Figure 1B) increase in mitochondrial autophagy.
While the control group had largely intact mitochondria, mitochondrial morphology in the treated
group had changed after 6 h of treatment. Mitochondria were found to be broken and aggregated in a
time-dependent manner (Figure 1B). Moreover, co-localization of GFP-LC3 and mitochondria indicated
that mitochondrial autophagy was enhanced with increase in treatment time. Bafilomycin A1 (BA1) is a
lysosome inhibitor that can strongly inhibit degradation of autophagosomes [29,30]. The samples were
added with BA1 at 8 h before sample collection and observed after 8 h of drug treatment. We found a
large increase in the number of autolysosomes, enhanced colocalization of broken mitochondria and
autolysosomes, and complete recovery of mitochondrial morphology, indicating that cisatracurium
besylate could induce mitochondrial autophagy. When the treatment time was extended to 24 h, cell
morphology changed from spindle to circular, and mitochondria were fully fragmented, indicating
that mitochondrial autophagy was hyperactivated in those cells (Figure 1B).
To further verify the relationship between cisatracurium besylate and mitochondrial autophagy,
we examined change in mitochondrial protein amount and status of transformation from LC3I
to LC3II. In mammalian cells, newly synthesized LC3 disperses in the cytoplasm. As autophagy
occurs, LC3I is transformed into LC3II, which is inserted into autophagic membranes [31]. Therefore,
transformation from LC3I into LC3II, measured as the ratio of LC3II to LC3I, is an indicator of degree
of autophagy [32,33]. Accordingly, HeLa cells and HUVECs (Figure 1C,D) were separately treated to
examine the expression of mitochondrial proteins, including Tim23 (mitochondrial inner-membrane
protein), TOM20 (mitochondrial outer-membrane protein), VDAC (mitochondria intermembrane
proteins) and autophagosome protein LC3. Compared with the control group, the ratio of LC3II to
LC3I increased gradually in the treatment group with both concentration and time, except for 2.5 µM
or 6 h treatment, which led to slight decrease in the ratio (Figure 1C,D). In addition, expression of
mitochondrial proteins such as Tim23, VDAC1 and Tom20 were also decreased in a time-dependent
manner. After addition of the lysosome inhibitor BA1, expression of mitochondrial proteins returned
to levels close to those in the control group. Identical results were observed in two different cell lines,
indicating that cisatracurium besylate could easily induce mitochondrial autophagy even at a low
concentration (5 µM).
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Figure 1. Cisatracurium triggers excessive mitochondrial autophagy in a dose- and time-dependent 
manner in mammalian cells. (A) GFP-LC3 and MitoDsred double fluorescent stable cell line was 
incubated with cisatracurium (0, 2.5, 5, 10, 25, 50, or 100 µM) for 12 h. GFP-LC3 (green) dot shows 
autophagosome-like structures. MitoDsred (red) denotes mitochondria. Arrows represent colocalization 
of LC3-positive autophagosome-like structures with mitochondria. Dotted white frames are  
enlarged parts of a cell. Bar = 30 µm; (B) GFP-LC3 and MitoDsred double fluorescent stable cells were 
incubated with cisatracurium (5 µM) for 0, 6, 12, or 24 h, in the presence or absence of the lysosome  
inhibitor Bafinomycin A1 (50 nM, B1793). Arrowheads represent colocalization of LC3-positive 
autophagosome-like structures with mitochondria. Bar = 30 µm. Arrows indicate colocalized  
LC3-positive vesicles with mitochondria; (C) HeLa (upper panel) or HUVEC (lower panel) was 
incubated with cisatracurium (0, 2.5, 5, 10, 25, or 50 µM) for 12 h. Samples were then subjected to 
immunoblot using antibodies against LC3, TIM23, TOM20, VDAC, or β-actin. Data are presented as 
representative images from three independent experiments, and the intensity of indicated bands was 
measured with ImageJ software and normalized by Beta-actin; (D) HeLa (upper panel) or HUVEC 
(lower panel) was incubated with cisatracurium (5 µM) for 0, 6, 12, or 24 h, in the presence or absence 
of the lysosome inhibitor Bafinomycin A1 (50 nM, B1793). Samples were then subjected to 
immunoblot using antibodies against LC3, TIM23, TOM20, VDAC, or β-actin. Data are presented as 
representative images from three independent experiments, and the intensity of indicated bands was 
measured with ImageJ software and normalized by Beta-actin. 
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Autophagosomes are double-membrane structures containing undigested cytoplasm or organelles 
(e.g., injured mitochondria, endoplasmic reticulum fragments). After maturation, they fuse with 
lysosomes. Autophagosomes show a classical double membrane structure under an electron 
microscope. At early stages, the electron density of its contents is the same as that of cytoplasm. 
Hence, it is easy to recognize autophagosomes. After autophagosomes and lysosomes fuse to  
form autolysosomes, a single-membrane structure that contains cytoplasmic contents at different 
stages of degradation is formed [36–39]. The control group showed oval mitochondria with complete 
Figure 1. Cisatracurium triggers excessive mitochondrial autophagy in a dose- and time-dependent
manner in mammalian cells. (A) GFP-LC3 and MitoDsred double fluorescent stable cell line was
incubated with cisatracurium (0, 2.5, 5, 10, 25, 50, or 100 µM) for 12 h. GFP-LC3 (green) dot
shows autophagosome-like structures. MitoDsred (red) denotes mitochon ria. Arrows represent
colocalization of LC3-positive autophagosome-like structure with mitochondria. Dotted white frames
are enlarged par s of a cell. Bar = 30 µm; (B) GFP-LC3 and MitoDsred double fluore cent stable
cells were incubated with cisatracurium (5 µM) for 0, 6, 12, or 24 h, in the presence or absence
of the lysosome inhibitor Bafinomycin A1 (50 nM, B1793). Arrowheads represent colocalization
of LC3-positive autophagosome-like structures with mitochondria. Bar = 30 µm. Arrows indicate
colocalized LC3-positive vesicles with mitochondria; (C) HeLa (upper panel) or HUVEC (lower panel)
was incubated with cisatracurium (0, 2.5, 5, 10, 25, or 50 µM) for 12 h. Samples were then subjected
to immunoblot using antibodies against LC3, TIM23, TOM20, VDAC, or β-actin. Data are presented
as representative images from three independent experiments, and the intensity of indicated bands
was measured with ImageJ software and normalized by Beta-actin; (D) HeLa (upper panel) or HUVEC
(lower panel) was incubated with cisatracurium (5 µM) for 0, 6, 12, or 24 h, in the presence or absence
of the lyso ome inhibitor Bafinomyc A1 (50 M, B1793). Samples were then subjecte to immunoblot
using antibo ies against LC3, TIM23, TOM20, VDAC, or β-actin. Data are presented as representative
images from three independent experiments, and the intensity of indicated bands was measured with
ImageJ software and normalized by Beta-actin.
2.2. Cisatracurium Besylate Promotes Autolysosome Formation
TEM is commonly used to directly observe the structure of autophagosomes [34,35].
Autophagosomes are double-membrane structures contai ing undigested cytoplasm or organelles
(e.g., injured mitochond ia, e doplasmic reticulum ragments). After maturati n, they fuse with
lysosomes. Autophagosomes show classi al double membrane stru ture under an lectron
microscope. At early stages, the electron density of its contents is the same as that of cytoplasm.
Hence, it is easy to recognize autophagosomes. After autophagosomes and lysosomes fuse to form
autolysosomes, a single-membrane structure that contains cytoplasmic contents at different stages
of degradation is formed [36–39]. The control group showed oval mitochondria with complete
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crista structure and clear cytoplasm (Figure 2). The drug treatment group showed formation
of autolysosomes in a dose-dependent manner (Figure 2). With increase in drug concentration,
the number of single-membrane autolysosomes increased. Notably, the degraded products appeared
as aggregates of black particles or were amorphous.
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Figure 2. Cisatracurium besylate induces autolysosome formation. HUVECs were incubated with
cisatracurium (0, 5, 25, or 100 µM) for 12 h. Samples were analyzed by electron microscopy.
Red arrows indicate autolysosomes. The number of the autolysomes increases in a concentration
dependent manner.
2.3. Cisatracurium Besylate Inhibits Proliferation of Endothelial Cells in Vitro
Cisatracurium besylate promotes breakage of mitochondria, degradation of mitochondrial
proteins, mitochondrial autophagy and drastic changes in cell morphology. Hence, we sought
to systematically study the effects of drugs at different concentration and time gradients on
endothelial cells in vitro. We found that the drug’s inhibiting effect on cell proliferation
was concentration-dependent (Figure 3A). Compared with the control group, proliferation of
endothelial cells in the drug treatment group showed a significantly linear decreasing trend.
The high-concentration treatment group showed the highest decrease in proliferation (p < 0.01)
(Figure 3A). The inhibitory effect of cisatracurium besylate on the proliferation activity of endothelial
cells was also time-dependent (Figure 3B). Compared with the control group, proliferation of
endothelial cells in the treatment group showed a significantly linear decreasing trend after treatment
at the same concentration (5 µM). The decrease in proliferation was the largest for treatment durations
between 6 and 12 h. Over this range of treatment duration, the differences between the control group
and the treatment groups as well as those among the treatment groups were all statistically significant
(p < 0.01) (Figure 3B).
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viability was analyzed by CCK assay; (C) HUVEC was incubated with cisatracurium (0, 5, 10, 25, 50, 
or 100 µM) for 12 h. Cells were stained by PI and Annexin-5 and then analyzed by flow cytometry to 
calculate the rate of apoptosis. Data are presented as mean ± SD from three independent experiments. 
p < 0.01; (D) HUVEC was incubated with cisatracurium (5 µM) for 0, 6, 12, or 24 h. Cells were stained 
with PI and Annexin-5, then analyzed by flow cytometry to calculate the rate of apoptosis. Data are 
presented as mean ± SD from three independent experiments. p < 0.01; (E) HUVEC was incubated 
with cisatracurium (0, 10, 25, 50, 100 µM) for 12 h. Samples were then subjected to immunoblot using 
antibodies against PARP or β-actin. Numbers indicate the normalized optical density ratio of cleaved 
PARP to β-actin. Data are presented as a representative image from three independent experiments. 
2.4. Cisatracurium Besylate Promotes Apoptosis of Endothelial Cells in Vitro 
We also used flow cytometry to investigate the extent of damage caused by cisatracurium 
besylate on endothelial cells in vitro. Results showed that apoptosis rate increased in the drug 
treatment group in a concentration- and time-dependent manner compared with the control group 
(Figure 3C,D). After 10 µM drug treatment for 24 h, endothelial cell apoptosis rate approached 60%, 
indicating that long-term application of high-dose cisatracurium besylate did harm endothelial cells 
in vitro (p < 0.01) (Figure 3D). 
PARP protein is used as a marker of apoptosis in cells. PARP is the main substrate of caspase 3, 
so PARP cleavage is usually considered an indicator of caspase 3 activation [40–43]. In the drug 
treatment group, beginning at cisatracurium besylate concentration of 10 µM, cleavage of PARP 
proteins could be detected (Figure 3E). Intriguingly, the gray value of cleavage strip did not show 
prominent gradient variations with increase in concentration, indicating activation of the autophagic 
Figure 3. Cisatracurium causes inhibition of cell proliferation and induction of cell death. (A) HUVEC
was incubated with cisatracurium (0, 5, 10, 25, 50, or 125 µM) for 12 h. Cell viability was analyzed
by CCK assay; (B) HUVEC was incubated with cisatracurium (10 µM) for 0, 6, 12, 24, or 45 h. Cell
viability was analyzed by CCK assay; (C) HUVEC was incubated with cisatracurium (0, 5, 10, 25, 50,
or 100 µM) for 12 h. Cells were stained by PI and Annexin-5 and then analyzed by flow cytometry to
calculate the rate of apoptosis. Data are presented as mean ˘ SD from three independent experiments.
p < 0.01; (D) HUVEC was incubated with cisatracurium (5 µM) for 0, 6, 12, or 24 h. Cells were stained
with PI and Annexin-5, then analyzed by flow cytometry to calculate the rate of apoptosis. Data are
presented as mean ˘ SD from three independent experiments. p < 0.01; (E) HUVEC was incubated
with cisatracurium (0, 10, 25, 50, 100 µM) for 12 h. Samples were then subjected to immunoblot using
antibodies ag inst PARP or β-actin. Numb rs indicate the normalized optical density ratio of cleaved
PARP to β-actin. Data are presented as a representative image from three independent experiments.
2.4. Cisatracurium Besylate Promotes Apoptosis of Endothelial Cells in Vitro
We also used flow cytometry to investigate the extent of damage caused by cisatracurium besylate
on endothelial cells in vitro. Results showed that apoptosis rate increased in the drug treatment group
in a concentration- and time-dependent manner compared with the control group (Figure 3C,D).
After 10 µM drug treatment for 24 h, endothelial cell apoptosis rate approached 60%, indicating that
long-term application of high-dose cisatracurium besylate did harm endothelial cells in vitro (p < 0.01)
(Figure 3D).
PARP protein is used as a marker of apoptosis in cells. PARP is the main substrate of caspase 3,
so PARP cleavage is usually considered an indicator of caspase 3 activation [40–43]. In the drug
treatment group, beginning at cisatracurium besylate concentration of 10 µM, cleavage of PARP
proteins could be detected (Figure 3E). Intriguingly, the gray value of cleavage strip did not show
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prominent gradient variations with increase in concentration, indicating activation of the autophagic
cell death pathway (as shown in Figures 1 and 2). At 100 µM, only weak PARP cleavage was detected
and both the cleaved and un-cleaved bands showed obvious decrease in intensity, indicating that most
endothelial cells were dead at this high concentration (Figure 3E).
2.5. Cell Death Induced by Cisatracurium Besylate Depends on Autophagy
Since both apoptosis and autophagy occur in cells treated with cisatracurium besylate, we asked
if autophagy follows or is independent of apoptosis. In order to address this, we used ATG5 knockout
cells to examine the drug effects in these autophagy deficient cells. The hexamer composed of
Atg12–Atg5 and Atg16 takes part in the formation of autophagosome precursors [44,45]. Besides,
the combination of Atg5 complex and autophagosome membrane can promote the recruitment of
LC3-PE to autophagic vacuoles [46]. These facilitate the combination of individual autophagosome
precursors to form a complete autophagosome. Some studies have shown significant inhibition of
autophagosome formation upon knocking out Atg5 [47,48]. WT MEF cells and Atg5 KO MEF cells
were treated with drugs at the range of concentrations described above. Cellular proliferation was
detected by the MTT assay method and cell growth was observed under a light microscope. increase in
drug concentration, proliferation of WT MEF cells declined linearly (Figure 4A,B). At 10 µM, significant
decrease in proliferation was observed. In addition, some cells could not adhere firmly, while some
took on irregular shapes, indicating the drug affected cell morphology. In contrast, the drug exerted
little effect on proliferation and growth of ATG5 KO MEFs (Figure 4A,B).
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Figure 4. Inhibition of cell proliferation and induction of cell death by cisatracurium is blocked in 
ATG5-deficient cells. (A) WT or ATG5 KO MEFs were incubated with cisatracurium (0, 10, 25, 50, or 
125 µM) for 12 h. Cell viability was analyzed by CCK assay; (B) WT or ATG5 KO MEFs were 
incubated with cisatracurium (0, 25, 50, 75, or 100 µM) for 12 h. Cells were observed by light 
microscopy. Bar = 100 µm; (C) WT or ATG5 KO MEFs were incubated with cisatracurium (5 µM)  
for 0, 6, 12, or 24 h in the presence or absence of Baf A1. Cells were stained by anti-LC3 (green) and 
anti-TOM20 (red) antibody. Bar = 15 µm; (D) WT or ATG5 KO MEFs were incubated with 
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Figure 4. Inhibition of cell proliferation and induction of cell death by cisatracurium is blocked
in ATG5-deficient cells. (A) WT or ATG5 KO MEFs were incubated with cisatracurium (0, 10, 25,
50, or 125 µM) for 12 h. Cell viability was analyzed by CCK assay; (B) WT or ATG5 KO MEFs were
incubated with cisatracurium (0, 25, 50, 75, or 100 µM) for 12 h. Cells were observed by light microscopy.
Bar = 100 µm; (C) WT or ATG5 KO MEFs were incubated with cisatracurium (5 µM) for 0, 6, 12, or 24
h in the presence or absence of Baf A1. Cells were stained by anti-LC3 (green) and anti-TOM20 (red)
antibody. Bar = 15 µm; (D) WT or ATG5 KO MEFs were incubated with cisatracurium (5 µM) for 0, 6,
12, or 24 h in the presence or absence of Baf A1. Samples were then subjected to immunoblot using
antibodies against LC3, Tim23, TOM20, ATG5 or β-actin. Numbers represent the normalized optical
density ratio of indicated bands to β-actin. Data are presented as a representative image from three
independent experiments, and the intensity of indicated bands was measured with ImageJ software
and normalized by Beta-actin.
In order to further examine whether the effects of cisatracurium besylate on cells rely on
mitochondrial autophagy, Atg5 KO MEF cells and WT MEF cells were treated with 10 µM cisatracurium
besylate. Observations under a fluorescence microscope revealed that in WT MEF cells, the number
of LC3-positive dots increased with time. Moreover, increased colocalization with mitochondria
was observed, suggesting occurrence of mitochondrial autophagy (Figure 4C). After drug treatment
for 24 h, addition of the lysosome inhibitor BA1 enhanced the colocalization of autolysosome and
mitochondrion, suggesting that mitochondrial protein degradation promoted by cisatracurium besylate
was mediated via autophagy (Figure 4C). In Atg5 KO MEF cells, neither LC3-positive fluorescent
puncta nor changes in mitochondrial morphology were observed over time (Figure 4C).
To further validate these results, WT MEF cells and Atg5 KO MEF cells were treated for various
durations, and expression of mitochondrial proteins was examined. In the ATG5 WT group, Tim23
and Tom20 degraded significantly faster than that in the ATG5 KO group after 12 or 24 h incubation
in a time-dependent manner. The ratio of LC3II to LC3I was the highest at 24 h. Treatment with the
lysosome inhibitor BA1 recovered expression of mitochondrial protein to a level close to that of the
control group (Figure 4D). As for ATG5 KO cells, no conversion from LC3I to LC3II was observed.
After addition of the lysosome inhibitor, degradation of mitochondrial proteins was not blocked,
indicating that cisatracurium besylate-induced mitochondrial turnover occurs through the autophagy
pathway (Figure 4D). Thus, our biochemical data and immunofluorescence results both show that
apoptosis induced by cisatracurium besylate is mediated via autophagy.
2.6. Cisatracurium Besylate Can Promote Cell Death Even in the Presence of the Apoptosis Inhibitor zVAD
As shown in Figure 4, addition of cisatracurium besylate into cells with autophagy deficiency
did not induce cell death and barely inhibited cell growth. This indicated that the damage caused by
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cisatracurium besylate to cells depended on the autophagy pathway. We next asked how cisatracurium
besylate would affect cells if they were treated with an apoptosis inhibitor.
As shown in Figure 5A, we treated wild-type MEF cells with the apoptosis inhibitor zVAD and
added cisatracurium besylate at various concentrations for 12 h. In the presence of 50 µM zVAD,
cisatracurium besylate caused linear decline in cell proliferation, and this effect increased with increase
in drug concentration. Light microscopic examination revealed significant morphological changes
(shrinking and rounding) in cells and decrease in cell number with increase in drug concentration.
At 75 µM, most cells died and severe reduction in cell number was observed.
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Figure 5. Cisatracurium promotes cell death even in the presence of the apoptosis inhibitor zVAD.
(A) WT MEFs were incubated with cisatracurium (0, 25, 50, 75, 100, or 125 µM) for 12 h in the presence
or absence of apoptosis inhibitor Z-VAD (50 µM). Cell viability was analyzed by CCK8 assay; (B) WT
MEFs were incubated with cisatracurium (0, 25, 50, 75, or 100 µM) for 12 h in the presence or absence
of apoptosis inhibitor Z-VAD. Cells were observed by light microscopy. Bar = 100 µm; (C) WT MEFs
were incubated with cisatracurium (10 µM) for 0, 6, 12, or 24 h in the presence or absence of Baf A1.
Cells were stained by anti-LC3 (green) and anti-TOM20 (red) antibody. Bar = 20 µm.
The ability of cisatracurium besylate to induce cell death even when apoptosis is inhibited
supports our hypothesis that cisatracurium besylate can injure cells through autophagic cell
death. Addition of the apoptosis inhibitor cisatracurium besylate (25 µM) induced autophagy
and mitochondrial breakage in wild-type MEFs. Even in the presence of the apoptosis inhibitor
zVAD, the number of LC3-positive dots increased significantly with time. In addition, mitochondrial
morphology also changed with change in treatment duration. Mitochondria became fragmented
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gradually and aggregated in the nucleus (Figure 5C). The total number of mitochondria decreased
gradually with the most significant change observed after treatment for 24 h. This suggested the
occurrence of mitochondrial autophagy in cells treated with cisatracurium besylate (Figure 5C).
3. Discussion
Cell death includes apoptosis and non-apoptotic necrotic cell death [49,50]. The latter
phenomenon is further divided into autophagic cell death, necrosis and PARP-mediated cell death.
Several differences exist between apoptosis and autophagic cell death [49,51,52]. Morphologically,
an apoptotic cell has condensed chromosome, fragmented nucleus, plenty of membrane blebs on the
plasma membrane, while autophagic cell death is characterized by the accumulation of autophagic
lysosomes. Biochemically, apoptosis is mainly mediated by activation of caspase, while autophagic cell
death is mediated via cascade reactions of the ATG protein caused by mTOR inhibition. The following
criteria are also used to identify autophagic cell death: (1) no involvement of apoptosis; (2) increased
autophagy flux; and (3) blockade of cell death upon blocking autophagy [53,54]. A general consensus
in the field is that weak or moderate autophagy can protect cells, but excessive autophagy leads to cell
death because of excessive digestion of necessary proteins, mitochondria and other essential organelles.
Cisatracurium besylate has various well-known advantages, so it is widely used in clinic.
However, some studies have suggested that cisatracurium besylate can affect cell proliferation [7].
Here we found that cisatracurium besylate injured cells via two mechanisms, namely cell apoptosis
and autophagic cell death. Due to the simplicity and limitations of previous studies, analysis on
the drug’s effect on cell proliferation had been done, but the mechanism of drug action remained
unknown. To investigate this, we designed a treatment scheme for HUVEC with several gradient
concentrations and durations and examined the effect on cells by multiple approaches. For example,
CCK-8 assay was used to determine cellular proliferation, the annexin V/PI double-staining method
was utilized to detect apoptosis, Western blot was conducted to determine the level of apoptotic
proteins, and immunofluorescence and transmission electron microscopy were adopted to examine
changes in mitochondrial autophagy. As in previous studies, we found that inhibition of endothelial
cells by cisatracurium besylate depended on drug concentration and treatment duration. More
importantly, we found that drug treatment could lead to mitochondrial fragmentation and excessive
activation of intracellular autophagy, thereby causing autophagic cell death. In addition, cell death
caused by the drug relied on activation of the autophagy pathway, since knocking out core autophagic
genes abolished induction of apoptosis and reduction of cell proliferation. Analysis by flow cytometry
indicated that in comparison to the control group, sum of the early apoptosis rate (E2) and late apoptosis
rate (E4) increased in a concentration- and time-dependent manner. After 6-h treatment with 100 µM
drug and 24-h treatment with 10 µM drug, endothelial cell mortality was close to 60%, indicating
that high dose and long duration of cisatracurium besylate treatment could damage endothelial
cells. In clinical practice, patients need to be continuously infused with cisatracurium besylate for
2–6 h depending on the case [55–60]. Occasionally, when the Patient–Ventilator Asynchrony occurs
in patients in intensive care with a respiratory machine control, 48 h continuous infusion of the
cisatracurium may be applied. During this time period, the drug has continuous effect on the patients’
tissues and cells. Considering our results showing cisatracurium besylate can damage cells, prolonged
use of cisatracurium besylate should be done with extreme caution.
Cleavage of PARP is generally used as an indicator of caspase 3 activation and of
apoptosis [41,61,62]. In the treatment group, PARP cleavage was detected at cisatracurium besylate
of 5 µM. The gray value of cleavage strip showed no gradient variations with increase in drug
concentration, i.e., PARP cleavage was not enhanced. In addition, results of PI/Annexin5 double
staining revealed that the number of apoptotic cells did not increase further with increase in drug
concentration beyond a certain level. This suggested that other non-apoptotic pathways contributed
to endothelial cell death induced by cisatracurium besylate. Further investigation is ecessary
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to determine whether the damage caused by cisatracurium besylate is caused by the metabolite
N-methyltetrahydropapaverine or excessive accumulation of peroxides (ROS).
The number of intracellular GFP-LC3 fluorescent puncta increased with treatment concentration
and duration. Furthermore, fragmentation and aggregation of mitochondria was also observed.
Electron microscopic observations revealed that the number of autolysosomes increased significantly
and mitochondrial proteins were degraded upon treatment with cisatracurium besylate. Notably,
decrease in mitochondrial protein levels was blocked in the presence of a lysosome inhibitor.
This suggested the occurrence of mitochondrial autophagy. Furthermore, cisatracurium besylate
could not induce apoptosis in cells in which the core autophagic gene ATG5 had been knocked out.
Notably, cisatracurium besylate was able to induce autophagic cell death even in the presence of the
apoptosis inhibitor zVAD. This is possibly because when the apoptosis pathway is blocked by zVAD,
the autophagic cell death pathway would be the major pathway which still works within the cell.
Altogether, these results establish autophagic cell death as a new mechanism for endothelial injury
caused by cisatracurium besylate.
4. Experimental Section
4.1. Cell Culture and Antibodies
Human umbilical vein endothelial cell (HUVEC), HeLa, GFP-LC3 and Mito-cherry HeLa
and mouse embryonic fibroblast (MEF) cells were grown in Dulbecco’s modified Eagle’s medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Hyclone, Logan, UT, USA)
and 1% penicillin/streptomycin (Beyotime, Shanghai, China, referred to as complete medium) at 37 ˝C
under 5% CO2. The following antibodies were used for western blot: anti-TIM23 (BD Biosciences
(San Diego, CA, USA) 611222), anti-TOM20 (BD Biosciences, 612278), anti-β-ACTIN (Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA) sc-47778), anti-LC3B polyclonal (Sigma-Aldrich (St. Louis,
MO, USA), L7543), anti-VDAC1 monoclonal (Abcam (Cambridge, MA, USA), ab14734), HRP
Affinipure goat anti-mouse IgG (Earthox (San Francisco, CA, USA), E030110), and HRP Affinipure goat
anti-rabbit IgG (Earthox, E030120). Purified mouse anti-CYTOCHROME c (BD Biosciences, 556432),
anti-LC3 polyclonal (MBL (Woburn, MA, USA), PM036), anti-LC3B monoclonal (MBL, M152–3)
antibodies were used for immunostaining.
4.2. Cell Viability Assay
The MTT Assay could be either used to measure the cell proliferation rate or the reduction in cell
viability. The reduction of tetrazolium salts by NAD(P)H-dependent cellular oxidoreductase enzymes
is now widely accepted as a reliable way to examine cell proliferation. HUVECs were seeded into
96-well plates (1 ˆ 104 cells per well). Drug treatments were performed the next day as designed.
Then, MTT (50 µL per well) was added to the culture medium and the culture dishes were incubated
at 37 ˝C for 4 h. The media in each well was removed and the insoluble products were dissolved in
150 µL DMSO for 10 min at room temperature. The optical density (O.D.) of each well was measured
at 490 nm in a spectrophotometer. The O.D. of the control group represents 100% cell viability.
4.3. Cell Apoptosis Assay
Cell apoptosis rate was measured by flow cytometry (Becton Dickinson, Mountain View, CA, USA).
The binding of annexin V-fluorescein isothiocyanate (FITC) to phosphatidylserine is an indicator of
apoptosis. Cells were double-stained with annexin V-FITC and propidium iodide (PI) according to the
manufacturer’s protocols, and cells were then analyzed by FACSan flow cytometer. Annexin V-FITC
positive cells reflected the relative proportion of apoptotic cells.
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4.4. Western Blot Analysis
Expressions of mitophagy and apoptosis related proteins were determined by Western blot.
Cells were lysed in RIPA buffer (25 mM Tris HCl, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS,
plus proteinase inhibitors and PMSF; Sigma). Protein concentration was mesured by a Bradford
assay kit (Pierce, Rockford, IL, USA), and samples (25 µg) were separated by 4%–12% gradient
SDS-PAGE. After transferred, the nitrocellulose membranes were blocked in 5% non-fat milk in
20 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween 20 for 30 min at room temperature, the membranes
were then incubated overnight at 4 ˝C with different primary monoclonal antibodies followed by
incubating with the horseradish peroxide-conjugated secondary antibody for 1 h at room temperature
and exposed to enhanced chemiluminescence reagents (ECL). Densitometric analysis (ImageJ, NIH,
Bethesda, MD, USA) was performed to quantify signal intensity.
4.5. Immunofluorescence Microscopy
Cells were grown to 60% confluence on a coverslip. After drug treatment, cells were washed with
ice-cold PBS, and fixed with freshly prepared 4% PFA at 37 ˝C for 20 min. Cells were permeabilized
by 0.1% Triton X-100 for 10 min. Cells were incubated with primary antibodies for 60 min, and after
washing with PBS, stained with fluorescent dye labeled-secondary antibody for 60 min. Images were
captured with a TCS SPF5 II Leica confocal microscope (Leica Microsystems, Wetzlar, Germany).
4.6. Electron Microscopy
Electron microscopy was done as previously described [35,63]. Cells were first fixed with 2%
glutaraldehyde in sodium cacodylate buffer (pH 7.4) at 37 ˝C for 2 h, and then dehydrated in a
graded ethanol series and embedded. Approximately 75-nm ultrathin sections were mounted on
nickel grids. The samples were then stained and visualized using a 120 kV Jeol electron microscope
(Peabody, MA, USA) (JEM-1400) at 80 kV. Images were captured using a Gatan-832 digital camera
(Pleasanton, CA, USA).
4.7. Statistical Analysis
Assays for characterizing cell phenotypes were analyzed by Student’s t-test, and correlations
between groups were calculated using Pearson’s test. p values <0.05 were deemed statistically significant.
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